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Abstract 
Objectives:  We aimed to elucidate the frequency and associations of MPO-ANCA positivity 
in patients without ANCA-associated vasculitis (AAV), in a large urban, multi-ethnic teaching 
hospital.  
Methods: Retrospective review of 200 patients identified as MPO-ANCA positive over a five 
year period at Royal Free Hospital, London, UK. 
Results:  The incidence of anti-MPO positivity in patients without AAV was 39.5%. 
Gastrointestinal tract disorders, infections and other connective tissue disorders made up 
the majority of diagnoses, and there was a higher incidence of other concomitant 
autoantibodies compared to the group with known AAV. Renal disease was common in non-
vasculitic patients with anti-MPO antibody positivity (occurring in 48%), the majority of 
which went on to renal biopsy to exclude vasculitic involvement. 
Conclusions: The high incidence of MPO-ANCA positivity in patients with non-vasculitic 
conditions highlights the need for careful clinical correlation and confirmatory tissue 
diagnosis.  
 
1 UCL Centre for Nephrology, Royal Free Hospital, London UK 
2 Clinical immunology laboratory, Royal Free NHS Trust, London UK 
 
Address for correspondence and reprint requests: Prof Alan D. Salama  
                                                                                           UCL Centre for Nephrology,  
                                                                              Royal Free Hospital,  
                                                                              Rowland Hill Street 
                                                                              London UK 
                                                                              +44 2077940500 x36007 














Advances in, and modifications of therapy in patients with ANCA-associated vasculitidies 
(AAV) have led to improved patient outcomes over the last decades (1). Historically, 
significant delays in diagnosis were common, as many symptoms are non-specific or may 
mimic infectious diseases. Increased awareness of these conditions and their milder 
variants, along with more widespread availability of ANCA testing, has potentially led to 
more rapid establishment of diagnosis. 
 
ANCA are autoantibodies directed against cytoplasmic constituents of neutrophils and 
monocytes, the two main specificities being for proteinase 3 (PR3) and myeloperoxidase 
(MPO). Two patterns of staining are found on indirect immunofluorescence: cytoplasmic (C-
ANCA), which usually occurs with PR3 specificity, and perinuclear (P-ANCA) that occurs with 
MPO (2). The combination of a pANCA immunofluorescence pattern with antibodies specific 
for MPO has been reported to have up to 99% specificity for the diagnosis of AAV (3). 
However, recent proposals, based on excellent performance of immunoassays, suggest that 
screening with immunofluorescence may be unnecessary (4). The increasing reliance on 
serological testing to establish a diagnosis has led to more widespread ANCA testing. With 
lower pre-test probabilities of underlying vasculitis in populations tested, there are 
increasing false positive tests which physicians have to be aware of. We have previously 
reported that up to 10% of positive PR3-ANCA serology may be found in patients without 
systemic vasculitis, but with infectious diseases, malignancies, other systemic autoimmune 
conditions or without obvious provoking factors (5). In this study we report on the 
frequency and associations of MPO-ANCA positivity in patients without primary vasculitis, 
and find it to be significantly higher (39.5%), and highlight the predominance of other 
autoimmune phenomena in these patients, as well as a high incidence of renal dysfunction 
which necessitates careful evaluation, with histological assessment in the majority, to 
exclude renal limited vasculitic disease. 
 
Materials and Methods 
 
A computerised search of all patients identified as MPO-ANCA positive in our local 
laboratory was performed between September 2010 and 2015. ANCA serology was 
examined by immunofluorescence on fixed neutrophil substrate and, if positive, by 
fluorescence enzyme immunoassays for the detection of antibodies to myeloperoxidase 
(EliA MPOs fluoroenzyeme immunoassay for anti-MPO antibodies, ThermoFisher). Upper 
limits of the normal range were MPO >10 IU/mL before 2014, MPO >5.0 IU/mL after 2014. 
 
Case notes and laboratory results were reviewed subsequently to establish if patients that 
tested positive for MPO-ANCA had a diagnosis of AAV or alternative diagnoses. 
 
Statistical analysis was conducted using GraphPad Prism (GraphPad Software, San Diego, 
CA). A p value <0.05 was considered to be statistically significant. Ethics board approval was 







Between September 2010 and 2015, 208 patients tested positive for MPO-ANCA. Eight 
patients did not have adequate clinical data available and were subsequently excluded from 
the analysis. Of the 200 patients analysed, 39% were men and the median (IQR) age of the 
cohort was 59 years (44-74). The majority of patients, 121 (60.5%) had an established or 
new diagnosis of AAV, while the remaining 79 (39.5%) did not have a diagnosis or evidence 
of primary systemic vasculitis. The median MPO-ANCA titre in the group with known AAV 
was 66(24-100) units/ml and the median serum creatinine 115(77-252.5) μmol/L compared 
with 16(12-30) units/ml and 81.5 (63-133.5) μmol/L respectively in the group without AAV 
(p<0.001) (Figure 1). The most common indications for testing ANCA status were joint pain 
and swelling (21.5%), persistent respiratory symptoms (12.7%) and acute kidney injury 
(8.9%).  
 
Of the 79 patients with positive MPO-ANCA without a diagnosis of AAV, 60 (75.9%) patients 
had an established alternative diagnosis including infections (n = 14, 17.7%), inflammatory 
bowel disease (n =10, 12.7%), autoimmune hepatitis (n = 9, 11.4%), systemic lupus 
erythematosous (n = 7, 8.8%), scleroderma (n=6,7.6%) and malignancy (n = 6, 7.6%). 
Nineteen patients had various symptoms that did not fulfil a single diagnosis (Figure 2). Sixty 
of the 79 patients (75.9%) also had other autoantibodies detected, the commonest of which 
was antinuclear antibody (ANA)(n=45, 56.7%), as compared with the MPO-ANCA AAV group, 
in whom only 21(17.3%) patients had other autoantibodies (p<0.0001). 
 
Thirty eight of the 79 patients without a known diagnosis of AAV had renal involvement as 
defined by an estimated glomerular filtration rate (eGFR) of less than 60 ml/min (n=28) 
and/or a urinary protein creatinine ratio greater or equal to 100mg/mmol (n=13) and/ or 
the presence of microscopic haematuria (n=10). Twenty two of these patients underwent a 
renal biopsy, and demonstrated various histological findings most commonly including lupus 
nephritis (n=8, 36.4%), chronic tubulointerstitial scarring (n=5, 22.8%) and diabetes (n=4, 
18.2%). 
 
Sixteen patients did not have a renal biopsy. Eleven (69%) of these patients had coexistent 
autoantibodies, mainly ANA (n=6), Rheumatoid factor (n=3) and anti-double stranded DNA 
(n=2). The majority (n=10, 62.5%) had autoimmune conditions known to be associated with 
anti-MPO antibodies. In two patients, MPO positivity was associated with positive hepatitis 
and HIV serology respectively. 
 
In the remaining four patients, no associations were found to explain the presence of 
MPOANCA. The median (IQR) follow-up of these four patients was 4(2-7) years. Their 
median MPO ANCA titre was 11(10-39) U/ml, eGFR 40(15-76) ml/min and age 69(51-86) 
years. One patient died at two year follow-up from unknown cause and the remaining three 







The combination of pANCA- and anti-MPO antibodies in patients with suspected small 
vessel vasculitis carries a specificity of 99% for MPA(3). However, in this cohort we report a 
39.5% incidence of unselected MPO-ANCA positive patients without primary vasculitis. 
Disorders of the gastrointestinal tract and liver (24%), infections (17.7%) and other 
connective tissue disorders made up the majority of diagnoses in the non-AAV group 
followed by several other potential associations including, medications and malignancy. The 
non-AAV group had a much higher incidence of other concomitant autoantibodies. This may 
suggest that the MPO-ANCA in this group of patients could be secondary to a polyclonal B- 
cell response in the presence of systemic inflammation seen in autoimmunity, infection or 
malignancy. Previous reports have also shown that pANCA can occur in a variety of medical 
conditions apart from AAV including chronic inflammatory processes such as tuberculosis, 
inflammatory bowel disease, malignancies, connective tissue diseases and following 
introduction of certain medications (6,7), and highlighted that anti-MPO positivity was less 
common in those patients without AAV. 
 
The significance of ANCA positivity in patients without AAV is unclear. Evidence from animal 
studies, which is supported by a case report of transplacental transfer of MPO-ANCA 
resulting in neonatal pulmono-renal syndrome, suggest that MPO-ANCA are pathogenic 
(8,9). It has also been shown that naturally occurring anti-MPO autoantibodies can exist in 
healthy individuals (10). However, these anti-MPO autoantibodies have epitope specificities 
that are different from those present in ANCA disease implicating immunodominant 
epitopes in the pathology of AAV (11). It is therefore possible that anti-MPO positivity in 
patients without AAV, like healthy controls, are directed against non-vasculitic disease-
causing epitopes, but specifically testing for these remains outside standard clinical care. In 
four of our patients with MPO-ANCA but without AAV, who had renal involvement and in 
whom we found no clinical association to explain the MPO-ANCA positivity, none developed 
AAV during a median four year follow-up. However, in studies using stored samples from US 
military recruits it was shown that MPOANCA can predate onset of the disease for up to 5 
years, which supports the need of long-term follow-up for these patients (12). 
 
Our incidence of 39.5% of MPO-ANCA positive patients with a variety of non-vasculitic 
conditions is significantly higher than the previously reported incidence of 9.7% for PR3-
ANCA in patients without AAV (5). In a retrospective review of 236 ANCA-positive patients, 
patients with an alternative diagnosis to AAV were more often anti-MPO positive than anti-
PR3 positive (58% vs. 42%) (6). interestingly, the main difference in these cohorts is that in 
non-AAV PR3- ANCA patients the commonest disease association was infection whereas in 
non-AAV MPOANCA patients were other autoimmune conditions. This is in keeping with 
dual positivity/overlap conditions that have shown a higher incidence of MPO, rather than 
PR3- ANCA in patients expressing other autoantibodies or with other immune mediated 
conditions, such as anti-GBM disease and scleroderma (13). It is possible that the HLA 
requirements for successful MPO presentation may be less restricted compared with PR3 
presentation, explaining the finding in various autoimmune diseases (14). The association of 
MPO-ANCA with renal limited vasculitis, in which extra-renal manifestations are absent, 
means that many MPOANCA patients with vasculitis present late with more advanced renal 
failure, often following routine screening blood tests (15). The high incidence of renal 
disease in the MPO-ANCA patients without vasculitis (48%) means that careful evaluation is 
required (often with renal biopsy) to secure the correct diagnosis and exclude a renal-
limited vasculitic process. 
 
In conclusion, we demonstrated a high incidence of MPO-ANCA positivity in patients with a 
variety of non-vasculitic conditions, significantly higher than the previously reported 
incidence of PR3-ANCA in patients without AAV. As detectable antibodies may predate 
disease onset, unexplained ANCA positivity requires long-term follow-up. In cases of 
diagnostic uncertainty confirmatory tissue diagnosis should be pursued as serology alone 
may be misleading. 
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Figure 1. a) Individual and median (horizontal bar) values of MPO-ANCA titres (units/ml)  in  
patients with MPO-ANCA and with (n = 121) or without (n = 79) a diagnosis of primary AAV  
(Mann Whitney U t-test p<0.0001) and  b) serum creatinine levels in (μmol/L)  patients with 
MPO-ANCA and with (n = 117) or without (n = 78) a diagnosis of primary AAV (Mann 
Whitney U t-test p<0.001). 
a)                                                                          b) 
 




































































Figure 2. Associated diagnoses in MPO-ANCA positive patients without known AAV (n=79), 











































Various diagnoses of uncertain significance
